In 1979, Alan ScoW introduced the technique of injection of Botulinum neurotoxin A into extraocular muscles to correct squint. Although others such as Bach-y-Rita,2 Crone3 and Jampolsky4 had suggested muscle injec tions with a variety of agents, Botulinum neu rotoxin A proved to have a reliable reproducible effect in appropriate dosage, causing a temporary flaccid paralysis of the injected muscle lasting 8-12 weeks. The paral ysis comes on about 3 days after injection, following which the deviation is reduced Or even reversed due to unopposed action of the ipsilateral antagonist muscle. Although studies on mouse skeletal muscle by Duchen5.6 showed that injected muscles showed myo fibrillar atrophy, muscular function seems to be regained fully as judged by clinical criteria of muscle power.
Materials and Methods
Having visited Alan Scott in San Francisco in 1981, we began treating patients for squint with Botulinum toxin in November 1982. From then until now we have treated 402 patients for squint and three for nystagmus. There were 227 female patients and 178 males. The youngest patient treated was 7 years old, the oldest was 87 years. The total number of injections given was 983, giving an average of 2.42 injections per patient. Table I shows the total numbers of injections per patient and Table II shows the muscles injected on each treatment session.
All injections were given by intramuscular injection, with the toxin dissolved in sterile isotonic saline, in an injection volume of 0.1 ml. Initially bipolar injection electrodes were used, but the vast majority of injections were given with monopolar injection elec trodes manufactured in the Electrodiagnostic Department at Moorfields Eye Hospital. Continuous electromyographic monitoring is performed during injection with both audible signal and oscilloscopic monitoring. Initially we used toxin manufactured by Dr Edward Schantz in Wisconsin and supplied to us by Alan Scott. Two hundred and ninety-eight injections were given of US-produced toxin in doses of 3.12xlO-4 �g and 1.56xlO-3 �g. We then changed to toxin manufactured by Pro fessor Melling's laboratory at Porton Down. To date, 695 injections have been given of the latter. As this formulation seems to have rather more biological activity, we use it in a dose of 6.25 x 10-5 Jig.
Indications for Treatment
(a) Concomitant Exotropia. This is the com monest indication for toxin therapy in our clinic. A total of 183 patients have been treated (45.2 per cent of the total). Of these, seven had diplopia. The remaining 176 had either a primary or much more commonly, a consecutive exotropia, although 31 patients had a secondary sensory exotropia due to uni lateral visual loss.
The total number treated was 102 (25.2 per cent). Five had diplopia, nine had a secondary esotropia in a blind eye and 88 had a primary or residual esotropia. A sur prisingly large number of mature patients with esotropia had never had
surgery because 'their parents did not believe in surgery'. Concomitant hypotropia. Three patients were treated for hypotropia (0.7 per cent), primarily for cosmetic reasons, although a secondary benefit was to assess the risk of post-operative diplopia. Dysthyroid Ophthalmopathy. We have treated 25 (6.2 per cent) patients with this condition. The preliminary results have been presented elsewhere7 and a more detailed study is in preparation. Twenty-one patients were treated for hypotropia by injections to the inferior rectus and four were treated for esotropia with injections to the medial rec tus. Injection of the inferior rectus in dysthyroid disease is technically difficult and usually injections are given through the lower lid. In the majority of patients the deviation recurs, so the treatment is of main value in the control of acute diplopia in the early stages of the con dition before surgery is indicated, although 6 patients seem to have been controlled to longterm single vision with toxin alone. The remarkable thing is that Botulinum toxin is as effective in this condition. Clearly, in the early stages of dysthyroid disease, the fibrotic changes we expect at surgery If the symptoms are bothersome, the effect is allowed t o wear off and the patient is none the worse. If the patient is not subjectively distressed, however, more definitive sur gery may be undertaken. Although other groups are also treated 'diagnostically', e.g. the unilateral aphakia group (above), there were 14 patients (3.5 per cent) in whom treatment was purely diagnostic, and we expect this proportion to increase. (n) Nystagmus. Three patients have been treated for nystagmus and oscillopsia. The first was a 66 year old man with brainstem multiple sclerosis and oscillopsia. He had injection of medial and lateral rectus on the same eye and his acuity improved from 6/36 to 6/18. The effect was not maintained and reinjec-tion one month later gave little relief. The second was a 31 year old man with Freidreich's ataxia, confined to a wheel cha:ir, with severe optic atrophy, gross horizontal nystagmus and oscillopsia. He has now had 7 treatments with injection of both medial and lateral rectus on one eye with subjective improvement of the oscillopsia. Injections need to be repeated at roughly 2 monthly intervals. The third patient was a 44 year old woman who had her right eye enucleated in infancy for retinoblastoma. From her earliest childhood she had been aware that she had oscillopsia in the primary position which improved if she adopted a head turn to the left and adducted the left eye. Kestenbaum surgery was suggested, but she was concerned about surgery on her only eye. Accordingly, she had a 'demonstration' in the form of an injec tion of Botulinum toxin to the left medial rectus. This produced the desired effect and she is soon to have surgery.
Injections in Children
We have little experience in treating children. Five have been treated under Ketamine anaesthesia. Of these, three have been effec tively diagnostic, in that the aim was to demonstrate whether it was possible to re-align the visual axes. Two have since had surgery, one had a surgical overcorrection where the muscles were known to be very scarred, and toxin was preferred. One had an acquired VI palsy and was beginning to sup press and lose her compensatory head pos ture. We are dubious about the application of toxin therapy to infantile squint but it has been advocated by others.ll
Complications
Fourty-three injections were followed by ptosis, usually partial. Nine patients had a subconjunctival haemorrhage after injection, and fifteen had affectation of a adjacent rectus muscle causing an acquired vertical deviation. The total of these was 67, which gives a rate of 6.8 per cent, and all complications were tran sient. Many patients complained of tempo rary diplopia in the field of action of the injected muscle. This always resolved within a few weeks and patients were warned prior to injections of this.
Outcome
Ninety-three patients have had surgery per formed. In 21 of these, the surgery was performed in conjunction with toxin pre treatment, as described under VI nerve palsy (above). Surgery has been recommended in 25 patients. In four patients, the initial devia tion was treated with Botulinum toxin, then surgery was recommended. Following this, a consecutive deviation developed and this has been treated with Botulinum toxin to main tain good cosmesis. This group might be expected to increase with time. Seventy patients continue to attend the Toxin Clinic on a regular basis. A further 152 have been dis charged, with advice to return in the event of deterioration of their current status. Forty one patients have achieved a functional result, i. e., binocular vision has been restored in the primary position and over a reasonable field, and the situation is currently stable on fol low-up of at least one year. Twenty patients have inadequate follow-up.
